博晖创新公告，公司控股子公司河北博晖与通盈集团签订《2019年之补充协议（二）》，就禄劝、姚 安、平度3个单采血浆站后续审批事宜达成补充约定。协议规定，自所有条款生效之日起24个月内，通 盈集团需完成上述3个单采血浆站的审批，或为河北博晖开发新的单采血浆站以置换未完成审批的浆 站。若未能完成审批，每未完成审批浆站，河北博晖有权要求8000万元股权转让及补偿款。 ...

Core Viewpoint - The announcement details a significant equity management agreement between Bohui Innovation and its controlling shareholder, Du Jiangtao, involving a 14.7001% stake in Hebei Bohui Biopharmaceutical Co., Ltd. [1] Group 1: Equity Management Agreement - Du Jiangtao will entrust the management of the 14.7001% stake in Hebei Bohui to Bohui Innovation for free, following a transaction where he acquired the stake from Beijing Tongying Investment Group for 506 million yuan [1] - After the management agreement, Bohui Innovation's total stake in Hebei Bohui will increase to 15.4216% [1] - The agreement allows Bohui Innovation to exercise shareholder rights, excluding profit distribution and residual property rights, which remain with Du Jiangtao [1] Group 2: Supplementary Agreement on Capital Increase - A supplementary agreement was signed between Hebei Bohui and Tongying Group regarding the approval of three single plasma collection stations, with a 24-month deadline for completion [1] - Tongying Group has the option to replace unapproved stations by developing new ones, with a compensation of 80 million yuan per station for any that fail to meet approval [1] - The payment of the second tranche of the equity transfer, amounting to 240 million yuan, is contingent upon the execution of this supplementary agreement [1]

Core Viewpoint - The announcement by Bohui Innovation regarding the introduction of strategic investor Tongying Group and the capital increase for its subsidiary Hebei Bohui highlights significant developments in the company's growth strategy and operational expansion [2]. Group 1: Strategic Investment - On August 5, 2019, the sixth board of directors of Bohui Innovation approved the introduction of Tongying Group as a strategic investor for its subsidiary Hebei Bohui [2]. - Tongying Group will invest by transferring 120 million shares (72% ownership) of Bohui Biological Pharmaceutical Co., Ltd. and providing cash of 446.75 million yuan for the capital increase [2]. Group 2: Operational Commitments - Tongying Group has committed to ensuring that five plasma collection stations in Luyuan, Yaoan, Shenzhou, Linxi, and Pingdu obtain necessary qualifications and pass inspections within 18 months after the share transfer [2]. - A supplementary agreement was signed in December 2021 to further solidify the investment terms and operational commitments [2]. Group 3: Recent Developments - On February 4, 2026, the eighth board of directors approved a supplementary agreement regarding the approval process for three plasma collection stations in Luyuan, Yaoan, and Pingdu [2]. - This supplementary agreement does not require approval from the company's shareholders [2].

格隆汇2月4日丨博晖创新(300318.SZ)公布，公司控股股东、公司控股子公司博晖生物制药（河北）有 限公司（简称"河北博晖"）股东杜江涛先生与北京通盈投资集团有限公司（简称"通盈集团"）签署了 《股权转让协议》，拟受让通盈集团持有的河北博晖14.7001%股权。为维护公司独立性，避免公司控 股股东与公司存在现实或潜在的同业竞争，公司控股股东杜江涛先生拟与公司签订《股权托管协议》， 拟将本次受让的河北博晖14.7001%股权委托公司无偿管理（除相关股权的利润分配权、利润分配请求 权、剩余财产分配权和剩余财产分配请求权外，杜江涛先生同意公司行使该等股权所对应的其他股东权 利）。该事项已经公司独立董事专门会议审核，并经公司第八届董事会第十七次会议审议通过。本次 《股权托管协议》签订后，杜江涛先生委托公司无偿管理河北博晖股权合计为15.4216%。 ...

每经AI快讯，博晖创新2月4日晚间发布公告称，公司第八届第十七次董事会会议于2026年2月4日在公 司会议室召开。会议审议了《关于与控股股东签订 <股权托管协议> 暨关联交易的议案》等文件。 每经头条（nbdtoutiao）——特朗普的"完美人选"颠覆美联储？解码凯文·沃什的"新政构想"：左手放水 右手抽水，要靠AI驯服通胀，拒做美债"大买家" （记者 王瀚黎） ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2026-005 北京博晖创新生物技术集团股份有限公司 关于控股子公司签订增资补充协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2026 年 2 月 4 日召开第八届董事会第十七次会议，审议通过了《关于控股子 公司签订增资补充协议的议案》，现就相关事项公告如下： 一、基本情况概述 公司于 2019 年 8 月 5 日召开第六届董事会第二十四次会议，审议通过了《关 于河北大安引入战略投资人并增资的议案》，同意公司控股子公司博晖生物制药 （河北）有限公司（曾用名："河北大安制药有限公司"，曾用简称："河北大安"， 以下简称"河北博晖"）引入"北京通盈投资集团有限公司"（以下简称"通盈集团"） 为战略投资人。双方签订《增资协议》，协议约定：通盈集团将以其所持博晖生 物制药股份有限公司（曾用名："中科生物制药股份有限公司"，以下简称"廊坊 博晖"）12,000 万股股份（持股比例 72%）及现金 44,675 万元对河北博 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2026-006 北京博晖创新生物技术集团股份有限公司 性别：男 国籍：中国 住址：北京市海淀区 关于与控股股东签订《股权托管协议》暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 2026年2月4日，公司控股股东、公司控股子公司博晖生物制药（河北）有限 公司（以下简称"河北博晖"）股东杜江涛先生与北京通盈投资集团有限公司（以 下简称"通盈集团"）签署了《股权转让协议》，拟受让通盈集团持有的河北博晖 14.7001%股权。为维护公司独立性，避免公司控股股东与公司存在现实或潜在的 同业竞争，公司控股股东杜江涛先生拟与公司签订《股权托管协议》，拟将本次 受让的河北博晖14.7001%股权委托公司无偿管理（除相关股权的利润分配权、利 润分配请求权、剩余财产分配权和剩余财产分配请求权外，杜江涛先生同意公司 行使该等股权所对应的其他股东权利）。该事项已经公司独立董事专门会议审核， 并经公司第八届董事会第十七次会议审议通过。本次《股权托管协议》签订后， 杜江涛先生委托公司无偿管理河 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2026-004 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第十七次会议于 2026 年 2 月 4 日在公司会议室召开，会议通知于 2026 年 1 月 23 日以专人送达、邮件通知或电话通知的方式送达各位董事，会议 由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本次 会议应出席董事 7 人，实际出席董事 7 人。本次会议的召集召开程序符合《公司 法》和《公司章程》的有关规定。 二、董事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《关于控股子公司签订增资补充协议的议案》 同意公司控股子公司博晖生物制药（河北）有限公司与北京通盈投资集团有 限公司签订《2019年<增资协议>之补充协议（二）》。 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于 控股子公司签订增资补充协议的公告》。 表决结果：同意7票，反对0票，弃权0票。同意票数占总票数的100%。 2、审议通过《关于与控股股东签订<股权托管协议>暨关联交易的议案》 北 ...

Group 1 - The company has developed a self-researched Nipah virus detection kit (PCR-fluorescent probe method) which has been launched for scientific research purposes [2] - The product is applicable in scenarios such as disease control monitoring and customs quarantine [2]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]